Clinical Trial

JMT106 Injection in the Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-28.
Trial Details
NCT Number NCT07275073
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Enrollment 200 participants
Start Date 2025-09-25
Primary Completion 2026-11-05 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-18